These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 14633962)

  • 1. Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion.
    Lee HC; Suh DJ; Ryu SH; Kim H; Shin JW; Lim YS; Chung YH; Lee YS
    Gut; 2003 Dec; 52(12):1779-83. PubMed ID: 14633962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion.
    Lee KM; Cho SW; Kim SW; Kim HJ; Hahm KB; Kim JH
    J Viral Hepat; 2002 May; 9(3):208-12. PubMed ID: 12010509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
    Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase.
    van Nunen AB; Hansen BE; Suh DJ; Löhr HF; Chemello L; Fontaine H; Heathcote J; Song BC; Janssen HL; de Man RA; Schalm SW
    Gut; 2003 Mar; 52(3):420-4. PubMed ID: 12584227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion.
    Yoon SK; Jang JW; Kim CW; Bae SH; Choi JY; Choi SW; Lee YS; Lee CD; Chung KW; Sun HS; Kim BS
    Intervirology; 2005; 48(6):341-9. PubMed ID: 16024938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Change of HBV DNA level as a predictor of HBeAg loss after lamivudine treatment].
    Jung JK; Lee CH; Kim EY; Jung JT; Choi JH; Han JM; Jin MI; Cho JY; Kim BS; Shin IH
    Korean J Hepatol; 2007 Dec; 13(4):513-20. PubMed ID: 18159149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
    Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of lamivudine in patients with hepatitis B e antigen-negative chronic liver diseases].
    Jeong Id; Park NH; Kim BC; Park JH; Seo KW; Kim DH; Joo KR; Kim DH
    Taehan Kan Hakhoe Chi; 2003 Jun; 9(2):69-78. PubMed ID: 12824746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
    Wong VW; Wong GL; Tsang SW; Hui AY; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL
    Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining age and HBsAg level predicts post-treatment durability of nucleos(t)ide analogue-induced HBeAg seroconversion.
    Yao CC; Lee CM; Hung CH; Wang JH; Hu TH; Lu SN; Changchien CS; Hsu MC; Chen CH
    J Gastroenterol Hepatol; 2015 May; 30(5):918-24. PubMed ID: 25532588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
    Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
    Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B.
    Liu CJ; Huang WL; Chen PJ; Lai MY; Kao JH; Chen DS
    World J Gastroenterol; 2004 Dec; 10(24):3574-8. PubMed ID: 15534909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression.
    Yeh CT; Hsu CW; Chen YC; Liaw YF
    J Clin Virol; 2009 Jun; 45(2):114-8. PubMed ID: 19451024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
    Yue W; Yuan H; Mao XR; Deng YD; Chen L
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients].
    Zhu M; Xu B; Yao GB
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):534-6. PubMed ID: 16042894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea.
    Song BC; Suh DJ; Lee HC; Chung YH; Lee YS
    Hepatology; 2000 Oct; 32(4 Pt 1):803-6. PubMed ID: 11003626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stringent cessation criterion results in better durability of lamivudine treatment: a prospective clinical study in hepatitis B e antigen-positive chronic hepatitis B patients.
    Wang L; Liu F; Liu YD; Li XY; Wang JB; Zhang ZH; Wang YZ
    J Viral Hepat; 2010 Apr; 17(4):298-304. PubMed ID: 19758278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
    Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
    Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients.
    Qiu YW; Huang LH; Yang WL; Wang Z; Zhang B; Li YG; Su TT; Zhou HY; Xu W; Wang XD; Dai YP; Gan JH
    Int J Infect Dis; 2016 Feb; 43():43-48. PubMed ID: 26523639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.